8-K: QuidelOrtho Announces Preliminary Q4 2024 Revenue, Meeting Expectations

QuidelOrtho reports preliminary unaudited fourth-quarter revenue for 2024, aligning with previous financial guidance.

Summary

• QuidelOrtho has released its preliminary unaudited revenue for the fourth quarter of 2024, which ended on December 29, 2024.
• The company expects total revenue to be between $702 million and $707 million, which is in line with their previously announced financial guidance.
• Non-respiratory revenue is estimated to be between $561 million and $563 million.
• Respiratory revenue is expected to be between $141 million and $143 million.
• The company will release its full fourth-quarter and full-year 2024 financial results on February 12, 2025.

Sentiment

Score: 7

Explanation: The sentiment is positive as the company met expectations and is looking forward to leveraging its 2024 efforts. However, the results are preliminary and subject to change, which introduces some uncertainty.

Positives

• The preliminary revenue results are in line with the company's previously announced 2024 financial guidance.
• The company expects to deliver top-line results above the mid-point of its 2024 financial guidance.
• QuidelOrtho has focused on high-growth opportunities and improved its cost structure through cost-saving initiatives.
• The company has realigned its leadership team.

Negatives

• The preliminary financial results are unaudited and subject to change as the company completes its year-end financial close process.
• Final financial results may vary materially from the preliminary estimates.

Risks

• The preliminary financial information is subject to adjustments based on the company's year-end financial close process.
• Fluctuations in demand for respiratory and non-respiratory products could impact future results.
• Supply chain, production, logistics, distribution, and labor disruptions could affect the company's performance.
• The integration of Quidel Corporation and Ortho Clinical Diagnostics Holdings plc presents challenges and costs.
• Macroeconomic, geopolitical, market, business, competitive, and regulatory factors could impact the company's business.

Future Outlook

The company expects to leverage the results of its 2024 efforts as it moves into fiscal year 2025 and will release full year results on February 12, 2025.

Management Comments

• Brian J. Blaser, President and CEO, stated that the company closed the year on a positive note and expects to deliver top-line results above the mid-point of their 2024 financial guidance.
• Management focused the team on high-growth opportunities, realigned leadership, and improved cost structure in fiscal year 2024.

Industry Context

This announcement is in line with the typical reporting cycle for public companies, providing a preliminary view of the company's performance before the full financial results are released. The focus on both respiratory and non-respiratory revenue is relevant given the company's diverse product portfolio in the diagnostics industry.

Comparison to Industry Standards

• QuidelOrtho's revenue guidance is in line with expectations, suggesting a stable performance compared to industry peers.
• Companies like Abbott and Roche, which also operate in the in vitro diagnostics space, typically report similar revenue breakdowns between different product categories.
• The focus on cost savings and efficiency improvements is a common theme in the industry, as companies strive to maintain profitability in a competitive market.

Stakeholder Impact

• Shareholders will be interested in the full financial results to be released on February 12, 2025.
• Employees may be impacted by the company's cost-saving initiatives and leadership realignment.
• Customers will be interested in the company's continued innovation and product development.
• Suppliers will be interested in the company's supply chain and production plans.

Next Steps

• The company will report its full fourth-quarter and full-year 2024 financial results on February 12, 2025.
• A conference call will be held on February 12, 2025, to discuss the financial results.

Key Dates

Keywords

QuidelOrtho, revenue, diagnostics, financial results, preliminary, unaudited, respiratory, non-respiratory, guidance, in vitro